Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

a study on Multiple Myeloma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Stefan Ciurea, MD

Description

Summary

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

Official Title

Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Keywords

Myeloma Multiple, Multiple Myeloma, Plasma Cell Neoplasms, Descartes 08

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients must be 18 years of age or older at the time of enrollment
  • High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).

You CAN'T join if...

  • Patients who are pregnant or lactating.
  • Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.

Locations

  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • Sarah Cannon Research Institute at Tennessee Oncology accepting new patients
    Nashville Tennessee 37203 United States

Lead Scientist at UC Irvine

  • Stefan Ciurea, MD
    Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 221 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cartesian Therapeutics
ID
NCT04816526
Phase
Phase 2 Multiple Myeloma Research Study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated
Contact us about this trial